TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06281262

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood collection
Description: The phenotypic characteristics of leukocytes will be compared between the groups to identify immunological markers of women at risk of preterm delivery.~Samples from the controls will be taken to define a baseline for the measured leukocyte populations.
Study: NCT05274750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depemokimab (GSK3511294)
Description: Depemokimab (GSK3511294) will be administered using a pre- filled syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Study: NCT05637255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1801
Description: 1 drop in the eligible eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1801
Description: 1 drop in the eligible eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYL1801
Description: 1 drop in the eligible eye
Study: NCT06281262

Intervention type: DIAGNOSTIC_TEST
Intervention: Swab sample collection
Description: Oral, vaginal and rectal swabs will be collected and stored for analysis of microbiota at the time of inclusion. At birth, oral, vaginal and rectal swabs and part of the placenta (placental tissue) will be collected for further analysis.
Study: NCT05972512

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mode of usage: Two times a day Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract of standardized biotin
Description: Mode of usage: Two times a day Route of administration: Oral

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract of standardised biotin with silica
Description: Mode of usage: Two times a day Route of administration: Oral
Study: NCT04372095

Intervention type: PROCEDURE
Intervention: oral smears
Description: oral smears

Intervention type: PROCEDURE
Intervention: oral smears
Description: oral smears
Study: NCT06583083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab with P-GEMOX Regimen
Description: Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P-GEMOX Regimen
Description: Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip
Study: NCT05316168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl 0.5% Injectable Solution
Description: During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: During adductor canal block participants will receive 2mg Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: During adductor canal block participants will receive 2mg Dexamethasone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration between Popliteal Artery and Capsule of the knee (iPACK)
Description: Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 5Mg-325Mg Tablet
Description: Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet 5Mg-325Mg Tablet
Description: Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control
Study: NCT05715450

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Falciformopexy for Treatment Perforated Peptic Ulcer
Description: use the falciform ligament on perforated peptic ulcer
Study: NCT05251441

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breast Milk Fortifier supplements
Description: Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breast Milk Fortifier supplements
Description: Current information is recommended for breast milk supplementation in premature babies. However, there is no consensus on when it will start. For breast milk supplementation, we planned to supplement one group of our patients with enteral nutrition of 50 ml/kg/day and the other group when they reached 100 ml/kg/day.
Study: NCT05504213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10352 combined with fulvestrant (Stage 1)
Description: Drug: HS-10352 HS-10352 will be administered at escalating doses orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28 day cycle.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10352 combined with fulvestrant (Stage 2)
Description: Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10352 combined with fulvestrant (Stage 2)
Description: Drug: HS-10352 participants will be enrolled into Cohort 2 (endocrine therapy-resistant) and Cohort 3 (endocrine therapy-sensitive or naïve) respectively and HS-10352 will be administered at the recommended dose identified in Part 1.~Drug: Fulvestrant Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study: NCT05122325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation TENS® EMS NMS60 device
Description: Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week at 10 Hz, with a pulse width of 200 μs and an intensity between 0 and 100 mA, which will be individually adjusted to each participant.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the frequency is raised to what has been established between 10Hz and there the intensity is increased without having to now reach the excitomotor threshold, as long as the physiotherapist notice it is enough (it must be tolerable).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital vibration with Ferticare 2.0® vibrator
Description: Women will be instructed in the use of the Ferticare 2.0® vibrator. Initially, a practice will be carried out , indicating that the frequency of use will be 70 Hz with an amplitude of 1.5 mm. It will be recommended to gradually increase its use over time, with a limit of 30 minutes a day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS® EMS NMS60 device_sham intervention
Description: Sham of TTNS intervention with Stimulation sessions with a TENS® EMS NMS60 device. These will be carried out for 30 minutes, once a week.~Inicially, frequency between 2-3 Hz, so that when the current passes, a contraction-relaxation will cause the first toe movement visually evident (excitomotor threshold).~Once verified, the intensity is decreased to lower the sensitive threshold of treatment.
Study: NCT06041243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game-Based Exercises
Description: Exercises aimed to improve postural balance with four different games
Study: NCT06477367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Based Breathing Exercises
Description: Researchers will present a 5-7 minute instructional video aimed at helping participants recall the technique for performing the exercises. These instructional videos will be sent to the researchers' mobile phones via WhatsApp. Participants will be instructed to perform the exercises three times a day for 15 minutes each, for a period of 30 days. To encourage regular exercise, participants will be provided with an exercise diary, and researchers will send reminder SMS messages at the same time every day. The control group will receive the clinic's routine dyspnea care protocol. After thirty days, final tests will be administered to both groups, and the research will be concluded.
Study: NCT06112613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive access to educational materials

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Utilize the WiseBag medication dispenser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Utilize the WiseBag medication dispenser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete an interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete an interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive healthcare provider follow ups as part of the CONCURxP program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive personalized text message reminders related to their medication tracking as part of the CONCURxP program
Study: NCT06435949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (as Citrate)
Description: intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl (as Citrate)
Description: intravenous anesthesia with propofol with fentanyl (group Fentanyl) and propofol with oxycodone (group Oxycodone)
Study: NCT04958928

Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: All patients received radiofrequncy ablation.
Study: NCT05445024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nalbuphine group
Description: nalbuphine ED95, dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sufentanil group
Description: sufentanil (1/1000\* nalbuphine ED95), dexmedetomidine ED95 and ondansetron 16mg were added into normal saline to a total of 100ml
Study: NCT05342740

Intervention type: OTHER
Intervention: collect whole blood, urine and stool samples
Description: collect whole blood, urine and stool samples

Intervention type: OTHER
Intervention: collect whole blood, urine and stool samples
Description: collect whole blood, urine and stool samples

Intervention type: OTHER
Intervention: collect whole blood, urine and stool samples
Description: collect whole blood, urine and stool samples
Study: NCT06362343

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban
Study: NCT05905887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib Mesylate, Paclitaxel
Description: Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day.
Study: NCT05634447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: CKD-391, QD, PO
Description: Drug: CKD-331, D337 QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: CKD-391, QD, PO
Description: Drug: CKD-331, D337 QD, PO
Study: NCT05302453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: Basic Body Awareness Therapy (BBAT), which is among the body-mind approaches, is also frequently used in the rehabilitation of patients with psychiatric disorders, pain, and chronic musculoskeletal system problems.
Study: NCT05261945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Routine Physical Therapy treatment with hot pack, TENS, and ultrasound helps in improving and relaxing the muscle spasm and soft tissue elasticity along pain reduction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy And Routine Physical Therapy
Description: Mulligan is consider one of the most effective technique of mobilization.it is also important treatment for neck pain so that many physiotherapist used mulligan by including several methods such as Natural Apophyseal Glides or Sustained Natural Apophyseal Glides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercises And Routine Physical Therapy
Description: Regular stretching helps increase your range of motion in the joints, improves blood circulation and posture and alleviates muscular tension throughout the body.
Study: NCT06153888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration rate
Description: Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltration rate
Description: Fluid removal during HD will be linear. The time on HD for fluid removal is adjusted after a formula for interdialytic weight gain / removal time (see Goto et al 2023).
Study: NCT06565169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Team Advance Care Planning With People with Alzheimer's Disease or a Related Dementia Training
Description: Included in arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: Included in arm/group descriptions
Study: NCT05075447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Control Treatment Program
Description: Intervention programs include Child Training and Training in real scenes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Control Treatment Program
Description: Intervention programs include Child Training and Training in real scenes
Study: NCT06090292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TUS
Description: 2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TUS
Description: 2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real FES
Description: Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real FES
Description: Twin Stim Plus EMS stimulator will be used to deliver FES to right and left hand opponens pollicis, first lumbrical and first dorsal interosseous muscles. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TUS
Description: 2 channel transducer from Sonic Concepts will be used to deliver 120s train of 20ms ultrasound bursts, repeated every 200ms (Pulse Repetition Frequency (PRF)=5Hz) however the ultrasound head will be flipped so that the active side faces away from the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham FES
Description: Twin Stim Plus EMS stimulator will be used to deliver FES to right and left biceps and long finger flexors. Parameters of stimulation are 40 Hz frequency, 300 microsecs pulse duration, amplitude as per participant tolerance and total stimulation time 30 mins with ON time of 4 secs and OFF time of 4 secs.
Study: NCT06420258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deeper endotracheal intubation
Description: After general anesthesia, endotracheal intubation was conducted using an ultrafine endoscope (GIF-XP260NS, Olympus Corp., Japan), which allows observation of the exact position and avoids blindness caused by laryngoscopy. To prevent balloon compression of the CE after inflating, the endotracheal intubation tube was inserted above the tracheal carina, roughly the upper thoracic esophagus.
Study: NCT05853731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green light emitting diode
Description: Green light therapy via light emitting diode (LED) in the 520 nanometers (nm) range at 4 lux intensity for up to 5 hours per day, as tolerated.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White light emitting diode
Description: Filtered white light via light emitting diode (LED) displayed for up to 5 hours per day, as tolerated
Study: NCT05198375

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound score (LUS)
Description: LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score (LUS)
Description: LU score (LUS) will be performed between 1 and 3 hours of life. LUS will be calculated by performing longitudinal scans of the chest in the anterior (midclavicular line), lateral (anterior axillary line) and posterior (posterior axillary line) area bilaterally using high-frequency linear or micro linear (hockey stick) probe. A score from 0 to 3 will be assigned to each area based on the ultrasound detected pattern.
Study: NCT06284629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neptune
Description: Neptune is a software algorithm that utilizes data from wrist-worn sensors to track Parkinson motor symptoms and displays them in an easy to understand graph. Neptune Care is a mobile app that includes a patient portal, where patients can self-report symptoms, view their motor data and get medication reminders, and a physician portal, where the treating physician can view the objective motor data and patient-reported outcomes prior to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical care
Description: Treatment and management according to standard clinical care
Study: NCT05594615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-235
Description: Subjects will receive EDP-235 once daily on Days 5-15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive midazolam once daily on Days 1 and 12
Study: NCT04683302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DUS biplanar catheterization
Description: biplanar view of both short and long axis view of the internal jugular vein improves anatomical awareness and potentially improves safety of venous catheterization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D US catheterization
Description: 2D short axis internal jugular vein catheterization
Study: NCT05594615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Subjects will receive rosuvastatin once daily on Days 2 and 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Subjects will receive caffeine once daily on Days 1 and 12
Study: NCT06505720

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic management of acute pediatric septic hip infecion
Description: Three-portals tractionless hip arthroscopy will be used to treat acute pediatric septic hip infection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open debridement of acute pediatric septic hip
Description: surgical drainage and debridement of acute septic hip in children via classic lateral approach
Study: NCT05863598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing protective factors
Description: Participants will watch some short movies and infographics, and will be asked to argue for the importance of body image flexibility, body functionality appreciation, etc.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing
Description: Participants will reflect and write about any cognitions or emotions they can have in relation to their bodies.
Study: NCT05530018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief contact intervention
Description: The brief contact intervention (BCI) will send out text messages to the participants. The text messages will include caring messages, reminders of appointments, and a link to a web page. The web page is anticipated to include safety planning, volitional helpsheet, and resources information. The text messages are anticipated to send out to the participants on a weekly base for 6 weeks in a row, and then change to monthly reminders. The monthly reminders are anticipated to include caring messages, reminders of appointments, and invitations to encourage the participants to click the previous web links again. The monthly reminders are anticipated to send out to the participants three times in a row. In the final reminder, the participants will be told that this intervention is going to end. In total, the participants will receive 9 texts within 5 months.
Study: NCT04840836

Intervention type: BEHAVIORAL
Intervention: Telehealth-supported LARC provision
Description: Provision of LARC in routine care will include a hybrid model of telehealth-supported long-acting reversible contraception (LARC) service provision in a network of 6 school-based health centers (SBHCs) in New York City that serve adolescents and young adult high school students age 13-22 years (hereafter referred to as adolescents).